Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma: Results from the phase III POLARIX study Meeting Abstract
| Authors: | Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; Izutsu, K.; Mehta-Shah, N.; Oberic, L.; Chauchet, A.; Jurczak, W.; Song, Y.; Greil, R.; Mykhalska, L.; Burgués, J. M. B.; Cheung, M. C.; Pinto, A.; Shin, H. J.; Hapgood, G.; Munhoz, E.; Abrisqueta, P.; Gau, J. P.; Hirata, J.; Jiang, Y.; Yan, M.; Lee, C.; Flowers, C.; Salles, G.; Collins, G. |
| Abstract Title: | Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma: Results from the phase III POLARIX study |
| Meeting Title: | 62nd Annual Scientific Meeting of the British Society for Haematology |
| Journal Title: | British Journal of Haematology |
| Volume: | 197 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Apr 3-5 |
| Meeting Location: | Manchester, United Kingdom |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2022-04-01 |
| Start Page: | 14 |
| End Page: | 16 |
| Language: | English |
| ACCESSION: | WOS:000776484300018 |
| PROVIDER: | wos |
| DOI: | 10.1111/bjh.18132 |
| PUBMED: | 35362090 |
| Notes: | Meeting Abstract: BSH22-OR11 -- Hybrid meeting, also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work